Будь ласка, використовуйте цей ідентифікатор, щоб цитувати або посилатися на цей матеріал: http://ir.librarynmu.com/handle/123456789/600
Назва: Metformin in neoadjuvant systemic therapy of breast cancer patients with metabolic syndrome
Автори: Liubota, Roman
Cheshuk, Valeriy
Zotov, Olexyy
Vereshchako, Roman
Anikusko, Mykola
Liubota, Iryna
Gur'yanov, Vitaliy
Ключові слова: breast cancer
metabolic syndrome
neoadjuvant systemic therapy
metformin
Дата публікації: 2018
Серія/номер: Archive of Oncology;2018; 24(1)
Короткий огляд (реферат): The aim of this prospective randomized trial was to investigate the influence of metformin on the effec- tiveness of neoadjuvant systemic therapy in breast cancer patients with metabolic syndrome. Patients and methods: The study included 72 patients (from 31 to 77 years of age) who received neoadjuvant systemic treatment for stage II-III breast cancer at the National Medical University named after O.O Bogomolets, Municipal City Clinical Oncological Center, Department of Oncology, Kyiv during 2010 - 2014. Metabolic syndrome was diagnosed in all patients according to the International Diabetes Federation criteria. They were divided in two groups: group 1 that included 36 patients with metabolic syndrome and breast cancer who did not intake metformin during neoadjuvant systemic therapy, and group 2 that included 36 patients with metabolic syndrome and breast cancer who received metformin with neoad- juvant systemic therapy. Results: Complete clinical response was identified in 2 (6%) patients from group 1 and 10 (27.5%) patients from group 2. Overall clinical response rate (cCR + cPR) was achieved in 28 (77.5%) patients treated with metformin compared to 9 (25%) patients from group 1. A stable disease was observed in 19 (53%) patients who were not taking metformin. The rate of pathological complete response was 26.5% (9 patients) in the metformin group and 6% (2 patients) in the non-metformin group. Conclusions: Combined neoadjuvant systemic anticancer therapy of breast cancer patient with metabolic syndrome with metformin has a higher clinical and pathological overall response rate than treatment without metformin.
URI (Уніфікований ідентифікатор ресурсу): https://doi.org/10.2298/AOO180312003L
http://ir.librarynmu.com/handle/123456789/600
Розташовується у зібраннях:Наукові публікації кафедри менеджменту охорони здоров’я

Файли цього матеріалу:
Файл Опис РозмірФормат 
Metformin in neoadjuvant systemic therapy of breast cancer patients with metabolic syndrome.pdf162,45 kBAdobe PDFПереглянути/Відкрити


Усі матеріали в архіві електронних ресурсів захищені авторським правом, всі права збережені.